FDA Approves Volcano's iFR® Pressure Measurement Modality for Use in Coronary Stent Guidance

This morning Volcano Corporation announced that the U.S. Food and Drug Administration has granted approval to the company's proprietary coronary pressure measurement modality, iFR (Instant wave-Free Ratio). iFR represents a significant advance in the field of functional measurement (FM), in which the actual flow pressures inside the coronary artery can be measured and the deficit caused by a coronary blockage or lesion can be accurately assessed.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news